Hepatitis C Virus

Pharma company expands study of Pegasys for hepatitis C in Latinos

Published in Hepatitis Weekly, November 28th, 2005

Roche announced that the company is investing more resources in treating the Latino community by expanding the largest study to date comparing hepatitis C treatment response rates in Latinos and non-Latino Caucasians treated with Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin, USP).

This study is one of the first conducted among this population, and will help researchers understand the response to hepatitis C treatment among the Latino community.

To recruit additional patients, Roche has increased the number of trial sites to 60 (up from 45) throughout the United States and Puerto Rico. When recruitment is complete, the study will enroll a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry